DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
"Providing an option like the pre-filled pen for DUPIXENTmay offer patients a more convenient experience that may help ease the daily burden of treating their condition."
- "Providing an option like the pre-filled pen for DUPIXENTmay offer patients a more convenient experience that may help ease the daily burden of treating their condition."
- The DUPIXENT pre-filled pen was designed to offer a more convenient and easy-to-use option for self-administration.
- "Patient needs drive innovation at Sanofi, and insights from patients helped inform the development of the pre-filled pen for DUPIXENT.
- DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant.